LSE · AOTI.L
AOTI, Inc.
£1.33+£0.01 (+0.76%)
AOTI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
Loading market information…
LSE · EAH.L · GBp
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 03:50 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
ECO Animal Health Group plc’s quoted price sits in the lower half of its reported 52-week range, 18.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
ECO Animal Health Group plc’s forward annual dividend is £0.16 per share, paid semi-annual. The forward yield is 17.06% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ECO Animal Health Group plc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ECO Animal Health Group plc, established in 1972 and based in New Malden, United Kingdom, focuses on the worldwide research, regulatory approval, and distribution of veterinary pharmaceutical solutions. The company's offerings include Aivlosin, a macrolide antibiotic specifically formulated to address digestive and respiratory illnesses in pigs and poultry. Additionally, its product range encompasses various generic drugs like Ecomectin, Ecoheart, Ecotraz, and Ecomintic. These endectocides and other antiparasitics are designed to manage and prevent parasitic infestations such as worms, ticks, and lice across a diverse array of animals, including cattle, sheep, pigs, horses, and dogs. ECO Animal Health Group also provides Chlortetracycline and Oxytetracycline for treating bacterial infections in swine, fowl, and bovine animals.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| £0.02 |
| £34.86M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£1.33+£0.01 (+0.76%)
AOTI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.67% below the high.
£0.90£0.00 (0.0%)
INSPECS Group plc’s quoted price sits in the upper half of its reported 52-week range, 14.29% below the high.
£0.68+£0.02 (+2.26%)
Venture Life Group plc’s quoted price sits in the upper half of its reported 52-week range, 5.56% below the high.
£1.90£0.00 (0.0%)
Kooth plc’s quoted price sits in the upper half of its reported 52-week range, 6.65% below the high.
£0.06+£0.00 (+0.92%)
Shield Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 56.0% below the high.
£0.10+£0.00 (+2.63%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£0.11+£0.00 (+1.11%)
Creo Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 38.51% below the high.
£6.80+£0.07 (+1.04%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 44.26% below the high.
